[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388999":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":10,"locations":25,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":10,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":59,"overallStatus":61,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient with autoimmune disease",null,"Selected using appropriate keywords in the Foundation Rothschild Hospital EMR, consenting to participate in the study.",[13],"Other: Questionnaire by phone call",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","Questionnaire by phone call","2 questionnaires : at inclusion and 4 months later. The exposure to hydroxychloroquine and the history of autoimmune disease is determined during the phone call along with other exposure factors. The symptoms presented by the patient are classified in \"Suggestive of a COVID-19 infection\" or \"Not suggestive of COVID-19 infection\" by a team of internists and infectious diseases specialists, by studying the questionnaires after the completion in a blind-manner regarding the hydroxychloroquine intake.",[9],[21],{"name":22,"affiliation":23,"role":24},"Guillaume DEBELLEMANIERE, MD","Fondation Adolphe de Rothschild","PRINCIPAL_INVESTIGATOR",[26],{"facility":23,"status":10,"city":27,"state":10,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":10},"Paris","75019","France","FR",{"type":32,"coordinates":33},"Point",[34,35],2.3488,48.85341,{"lat":35,"lon":34},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100388999","association-between-long-term-hydroxychloroquine-treatment-and-outcome-of-a-history-of-symptoms-suggestive-of-covid-19-infection-during-the-epidemic-period-in-france-in-patients-with-autoimmune-disease-100388999",false,"NCT04345159","Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","COVCALL","Inclusion Criteria:\n\n* History of Systemic Lupus Erythematosus, Rheumatoid arthritis, Sjogren's Syndrome or Psoriatic Arthritis.\n\nExclusion Criteria:\n\n* beginning, or end, of an hydroxychloroquine treatment between Jan 1, 2020 and day of the phone call.\n* Bad treatment compliance","ALL","18 Years",{"count":49,"type":50},572,"ACTUAL","OBSERVATIONAL","This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.",[54,55,56,57,58],"SARS-CoV-2","Systemic Lupus Erythematosus","Rheumatoid Arthritis","Sjogren's Syndrome","Psoriatic Arthritis",[60],"Hydroxychloroquine","COMPLETED","2021-01-06",{"date":64,"type":50},"2021-01-07",{"date":66,"type":50},"2020-04-17",{"date":68,"type":50},"2020-11-30",{"name":5,"class":6},1]